Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Imunon: Q1 Earnings Insights

Imunon (NASDAQ:IMNN) reported its Q1 earnings results on Thursday, May 11, 2023 at 08:00 AM. Here’s what investors…
byBenzinga Insights
May 11, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Imunon (NASDAQ:IMNN) reported its Q1 earnings results on Thursday, May 11, 2023 at 08:00 AM.

Here’s what investors need to know about the announcement.

Earnings

Imunon missed estimated earnings by 4.62%, reporting an EPS of $-0.68 versus an estimate of $-0.65.

Revenue was down $125 thousand from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.76 which was followed by a 2.36% drop in the share price the next day.

Here’s a look at Imunon’s past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate -0.85 -0.81 -1.12 -0.99
EPS Actual -1.61 -0.87 -0.87 -1.82
Revenue Estimate 120K 110K 80K 100K
Revenue Actual 125K 125K 125K 125K

To track all earnings releases for Imunon visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Tilray’s Diversified Growth Strategy Is Paying Off, Here’s What’s Behind 34% YoY Revenue Increase In Q2

By Jelena Martinovic
January 9, 9:54 AM
Canadian cannabis company Tilray reported a 34% increase in revenue in its second quarter of fiscal 2024. The company reported revenue of $194 million, up from $145 million in the same period last year. Tilray's cannabis net revenue increased 35% to $67 million, while beverage alcohol net revenue increased 117% to $47 million. Distribution net revenue also rose to $67 million, compared to $60 million in the same quarter last year. The company's gross profit increased 11% to $47 million, with adjusted gross profit up 18% to $52 million. Net loss in the second quarter amounted to $46 million, compared to a net loss of $62 million in the same period last year. Adjusted EBITDA stood at $10.1 million, down from $11 million in Q2 2023.

TLRY